Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD4 CAR T cells
- Development stage
- Unknown
- Lead developer
- iCell Gene Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD4 CAR T cells are a type of chimeric antigen receptor (CAR) T-cell therapy developed by iCell Gene Therapeutics. This cell therapy is being investigated in a Phase I clinical trial for the treatment of relapsed and/or refractory T cell lymphoma. The treatment involves administering either fresh or thawed CAR T cells via intravenous injection following lymphodepleting chemotherapy.
- Other names
- CD4-specific CAR T CellsCD-4-specific CAR T CellsCD 4-specific CAR T Cells
02
Targets
CD4 (T lymphocyte surface antigen)
Beyond the preview
Go deeper on CD4 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD4 CAR T cells.